These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2080983)

  • 21. Percutaneous absorption, metabolic profiling, and excretion of the penetration enhancer azone after multiple dosing of an azone-containing triamcinolone acetonide cream in humans.
    Wiechers JW; Drenth BF; Jonkman JH; de Zeeuw RA
    J Pharm Sci; 1990 Feb; 79(2):111-5. PubMed ID: 2324957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corneal endothelial changes with azone, a penetration enhancer.
    Durand-Cavagna G; Duprat P; Molon-Noblot S; Delort P; Rozier A
    Lens Eye Toxic Res; 1989; 6(1-2):109-17. PubMed ID: 2488011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the effect of occlusive dressings on lamellar bodies in the stratum corneum and relevance to transdermal absorption.
    Kennish L; Reidenberg B
    Dermatol Online J; 2005 Dec; 11(3):7. PubMed ID: 16409903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Synthetical evaluation of promoting effect of some kinds of transdermal enhancers with grey relational cluster method].
    Wang H; Li X; Xu BL; Xu WM
    Zhongguo Zhong Yao Za Zhi; 2004 May; 29(5):417-20. PubMed ID: 15706891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal delivery systems.
    Merkle HP
    Methods Find Exp Clin Pharmacol; 1989 Mar; 11(3):135-53. PubMed ID: 2657273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percutaneous absorption and elimination of the penetration enhancer Azone in humans.
    Wiechers JW; Drenth BF; Jonkman JH; de Zeeuw RA
    Pharm Res; 1987 Dec; 4(6):519-23. PubMed ID: 3508567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Oleyl pyroglutamate for use as transdermal enhancer and its enhancing mechanism].
    Cheng ZY; Chen HF
    Yao Xue Xue Bao; 2003 May; 38(5):384-7. PubMed ID: 12958846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclodextrins: application in different routes of drug administration.
    Shimpi S; Chauhan B; Shimpi P
    Acta Pharm; 2005 Jun; 55(2):139-56. PubMed ID: 16179128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermal drug delivery: basic principles for the veterinarian.
    Mills PC; Cross SE
    Vet J; 2006 Sep; 172(2):218-33. PubMed ID: 16324855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute.
    Wokovich AM; Prodduturi S; Doub WH; Hussain AS; Buhse LF
    Eur J Pharm Biopharm; 2006 Aug; 64(1):1-8. PubMed ID: 16797171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of transdermal drug delivery: chemical and physical approaches.
    Asbill CS; El-Kattan AF; Michniak B
    Crit Rev Ther Drug Carrier Syst; 2000; 17(6):621-58. PubMed ID: 11204737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chirality and its implications in transdermal drug development.
    Reddy IK; Kommuru TR; Zaghloul AA; Khan MA
    Crit Rev Ther Drug Carrier Syst; 2000; 17(4):285-325. PubMed ID: 10958245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thermodynamic study on enhancement of percutaneous penetration of drugs by Azone.
    Ito Y; Ogiso T; Iwaki M
    J Pharmacobiodyn; 1988 Nov; 11(11):749-57. PubMed ID: 3236208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transdermal drug delivery systems: skin perturbation devices.
    Brown MB; Traynor MJ; Martin GP; Akomeah FK
    Methods Mol Biol; 2008; 437():119-39. PubMed ID: 18369965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques.
    Agyralides GG; Dallas PP; Rekkas DM
    Int J Pharm; 2004 Aug; 281(1-2):35-43. PubMed ID: 15288341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vesicular carriers for dermal drug delivery.
    Sinico C; Fadda AM
    Expert Opin Drug Deliv; 2009 Aug; 6(8):813-25. PubMed ID: 19569979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Azone-induced changes on corneal endothelium in rabbits].
    Xu Y; Chen Z; Song J; Jin W; Li J
    Zhonghua Yan Ke Za Zhi; 1998 Jan; 34(1):25-7. PubMed ID: 11877145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iontophoretic drug delivery.
    Kalia YN; Naik A; Garrison J; Guy RH
    Adv Drug Deliv Rev; 2004 Mar; 56(5):619-58. PubMed ID: 15019750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced transdermal delivery of atenolol from the ethylene-vinyl acetate matrix.
    Cho CW; Shin SC
    Int J Pharm; 2004 Dec; 287(1-2):67-71. PubMed ID: 15541913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies.
    Panchagnula R; Bokalial R; Sharma P; Khandavilli S
    Int J Pharm; 2005 Apr; 293(1-2):213-23. PubMed ID: 15778059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.